<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01944969</url>
  </required_header>
  <id_info>
    <org_study_id>14767B</org_study_id>
    <secondary_id>2012-004169-42</secondary_id>
    <nct_id>NCT01944969</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder</brief_title>
  <official_title>Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in
      patients with Major Depressive Disorder (MDD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This extension safety study was terminated early because one of the lead-in studies (14571A)
      in elderly was terminated and because the Sponsor considered that sufficient long-term safety
      data has already been collected in the development programme in the population aged 18-65
      yrs.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated because the lead-in study (14571A) in elderly was terminated; see
    Detailed Description.
  </why_stopped>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Number of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Number of withdrawals</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour. The electronic C-SSRS (eC-SSRS) is a patient-rated electronic version using interactive voice response technology. A structured CSSRS script of standardised questions, follow-up prompts, error-handling and scoring conventions is used for administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depressive Symptoms</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>The Montgomery and Aasberg Depression Rating Scale (MADRS) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients in Remission</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Based on a pre-specified MADRS total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Clinical Global Impression - Severity of illness (CGI-S) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related Quality of Life</measure>
    <time_frame>From baseline to Week 52</time_frame>
    <description>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-(SF)) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health-related Quality of Life</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The EuroQoL 5 Dimensions 5L version (EQ-5D-5L) Visual Analogue Scale (VAS) is a patient-reported assessment designed to measure the patient's wellbeing. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems) and a single summary index (from 0 to 1) can be calculated. The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Brexpiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole</intervention_name>
    <description>1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)</description>
    <arm_group_label>Brexpiprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is judged to benefit from adjunctive treatment with brexpiprazole
             according to the clinical opinion of the investigator.

          -  The patient had MDD at entry in lead-in brexpiprazole studies, NCT01838681 / 14570A or
             NCT01837797 / 14571A, diagnosed according to DSM-IV-TR™.

          -  The patient agrees to protocol-defined use of effective contraception.

        Exclusion Criteria:

          -  The patient has a disease or takes medication that could, in the investigator's
             opinion, interfere with the assessments of safety, tolerability, or efficacy, or
             interfere with the conduct or interpretation of the study.

          -  The patient has been diagnosed with a psychiatric disorder other than MDD during the
             lead-in studies NCT01838681 / 14570A or NCT01837797 / 14571A.

          -  The patient, in the opinion of the investigator or according to C-SSRS, is at
             significant risk of suicide.

          -  The patient has any relevant medical history or current presence of systemic disease.

          -  The patient has, at the Baseline Visit an abnormal ECG that is, in the investigator's
             opinion, clinically significant.

          -  The patient has a moderate or severe ongoing adverse event related to study medication
             from the lead-in studies considered of potential safety risk by the investigator.

          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol or
             is unsuitable for any reason.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US008</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004169-42/results</url>
    <description>EudraCT (EMA) Result Posting</description>
  </link>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2013</study_first_submitted>
  <study_first_submitted_qc>September 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2013</study_first_posted>
  <results_first_submitted>August 17, 2015</results_first_submitted>
  <results_first_submitted_qc>February 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2016</results_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Brexpiprazole and ADT</title>
          <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with IMP</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative or other reasons</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Brexpiprazole and ADT</title>
          <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.12" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety</title>
        <description>Number of adverse events</description>
        <time_frame>From baseline to Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole and ADT</title>
            <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Number of adverse events</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability</title>
        <description>Number of withdrawals</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>26 patients were withdrawn; the reason for withdrawal was not poor tolerability, but mainly (23 patients) because the study was terminated. Please see withdrawn reasons in the participant flow section for the other reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole and ADT</title>
            <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability</title>
          <description>Number of withdrawals</description>
          <population>26 patients were withdrawn; the reason for withdrawal was not poor tolerability, but mainly (23 patients) because the study was terminated. Please see withdrawn reasons in the participant flow section for the other reasons.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)</title>
        <description>The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour. The electronic C-SSRS (eC-SSRS) is a patient-rated electronic version using interactive voice response technology. A structured CSSRS script of standardised questions, follow-up prompts, error-handling and scoring conventions is used for administration.</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>all-patients treated set (APTS)</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole and ADT</title>
            <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)</title>
          <description>The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour. The electronic C-SSRS (eC-SSRS) is a patient-rated electronic version using interactive voice response technology. A structured CSSRS script of standardised questions, follow-up prompts, error-handling and scoring conventions is used for administration.</description>
          <population>all-patients treated set (APTS)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No suicidal ideation or behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any non-suicidal self-injurious behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preparatory action towards imminent suicidal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not fatal suicide attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Depressive Symptoms</title>
        <description>The Montgomery and Aasberg Depression Rating Scale (MADRS) total score</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>None of the patients completed the study. A total of 26 patients were enrolled when the study was prematurely terminated(Planned: 1184 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole and ADT</title>
            <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1,2, or 3 mg/day, once daily dose, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Depressive Symptoms</title>
          <description>The Montgomery and Aasberg Depression Rating Scale (MADRS) total score</description>
          <population>None of the patients completed the study. A total of 26 patients were enrolled when the study was prematurely terminated(Planned: 1184 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients in Remission</title>
        <description>Based on a pre-specified MADRS total score</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>No patients completed the study. Only 26 patients were enrolled at prematurely study termination (Planned: 1184 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole and ADT</title>
            <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients in Remission</title>
          <description>Based on a pre-specified MADRS total score</description>
          <population>No patients completed the study. Only 26 patients were enrolled at prematurely study termination (Planned: 1184 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Global Impression</title>
        <description>Clinical Global Impression - Severity of illness (CGI-S) score</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>No patients completed the study. Only 26 patients were enrolled at prematurely study termination (Planned: 1184 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole and ADT</title>
            <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Global Impression</title>
          <description>Clinical Global Impression - Severity of illness (CGI-S) score</description>
          <population>No patients completed the study. Only 26 patients were enrolled at prematurely study termination (Planned: 1184 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health-related Quality of Life</title>
        <description>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-(SF)) total score</description>
        <time_frame>From baseline to Week 52</time_frame>
        <population>No patients completed the study. Only 26 patients were enrolled at prematurely study termination (Planned: 1184 patients).</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole and ADT</title>
            <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health-related Quality of Life</title>
          <description>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-(SF)) total score</description>
          <population>No patients completed the study. Only 26 patients were enrolled at prematurely study termination (Planned: 1184 patients).</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Health-related Quality of Life</title>
        <description>The EuroQoL 5 Dimensions 5L version (EQ-5D-5L) Visual Analogue Scale (VAS) is a patient-reported assessment designed to measure the patient’s wellbeing. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems) and a single summary index (from 0 to 1) can be calculated. The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>No patients completed the study. Only 26 patients were enrolled at prematurely study termination (Planned: 1184 patients). Due to the limited number of enrolled patients, no data were summarised for reporting and the data did not allow for any meaningful analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole</title>
            <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Health-related Quality of Life</title>
          <description>The EuroQoL 5 Dimensions 5L version (EQ-5D-5L) Visual Analogue Scale (VAS) is a patient-reported assessment designed to measure the patient’s wellbeing. It consists of 5 descriptive items (mobility, self-care, usual activities, pain/discomfort, and depression/anxiety) and a visual analogue scale (VAS) of the overall health state. Each descriptive item is rated on a 5-point index ranging from 1 (no problems) to 5 (extreme problems) and a single summary index (from 0 to 1) can be calculated. The VAS ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).</description>
          <population>No patients completed the study. Only 26 patients were enrolled at prematurely study termination (Planned: 1184 patients). Due to the limited number of enrolled patients, no data were summarised for reporting and the data did not allow for any meaningful analyses.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to Week 52</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Brexpiprazole and ADT</title>
          <description>Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
Brexpiprazole: 1, 2, or 3 mg/day, once daily dose, tablets, orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>H. Lundbeck A/S</name_or_title>
      <organization>H. Lundbeck A/S</organization>
      <phone>+45 36301311</phone>
      <email>LundbeckClinicalTrials@lundbeck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

